+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06731270

Phase II Trial of Diclofenac with Single Agent Immunotherapy for Treating Metastatic Non-Small Cell Lung Cancer with Early Progression Signs

Led by Emory University · Updated on 2026-02-12

20

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of diclofenac, a non-steroidal anti-inflammatory drug NSAID, in patients with metastatic non-small cell lung cancer NSCLC who are already receiving single agent immunotherapy. This phase II trial aims to assess whether diclofenac can improve treatment outcomes by reducing inflammation and tumor growth when combined with immunotherapy drugs such as pembrolizumab, atezolizumab, nivolumab, or cemiplimab. The study also explores changes in immune system markers and tumor environment related to this combination therapy. Participants receive diclofenac orally twice daily along with their standard immunotherapy given on the first day of each treatment cycle, which repeats every 21 or 28 days provided there is no disease progression or unacceptable side effects. During the study, patients undergo blood sample collections and imaging scans including CT, PET, or MRI to monitor disease status and immune changes. After completing treatment, patients are followed every 12 weeks for up to one year. Throughout the trial, researchers evaluate clinical benefit rate at 12 weeks as the primary outcome, along with safety, response rates, progression-free survival, overall survival, and duration of response. Blood tests and imaging help assess disease progression and immune response. The study includes close monitoring for side effects and treatment tolerance, with follow-up visits extending one year after treatment ends to observe long-term outcomes and patient health.

CONDITIONS

Brief Title

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Research Team

K

Kajona McCall

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here